Skip to main content
DARE
NASDAQ Life Sciences

Dare Bioscience Reports Improved Q1 Results, Positive Phase 3 Data, and Imminent First Product Revenue

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.95
Mkt Cap
$41.64M
52W Low
$1.27
52W High
$9.19
52W Position info
132% above low
Off High info
68% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

DARE has more than doubled off its 52-week low of $1.27 on elevated volume (2.0× avg).

Summary

Dare Bioscience reported improved Q1 2026 financial results, including a reduced net loss and increased revenue, while extending its cash runway into Q4 2026. The company also announced positive interim Phase 3 data for Ovaprene and expects to record its first direct product revenue in June 2026.


Key Events · Earnings and Guidance · DARE

  • Q1 2026 Financial Results

    Net loss improved to $(3.0) million from $(4.4) million year-over-year, with revenue increasing to $0.2 million. Cash and cash equivalents stood at $18.5 million as of March 31, 2026.

  • Cash Runway Extended

    Recent capital raises have extended the company's cash runway into Q4 2026, providing crucial liquidity in the context of prior going concern warnings.

  • Ovaprene Phase 3 Progress

    Received a second positive Data Safety Monitoring Board (DSMB) review for interim safety and efficacy data from its Phase 3 clinical trial, with the study continuing without modification. Enrollment completion is expected in 2026.

  • First Product Revenue Imminent

    Anticipates recording its first direct product revenue in June 2026 with the commercial launch of Flora Sync LF5, and DARE to PLAY dispensing is expected to commence in Summer 2026.


Analysis · DARE · Life Sciences

This filing is critical as it provides a comprehensive update on Dare Bioscience's efforts to achieve commercialization and financial stability, following previous concerns about its ability to continue as a going concern. The improved Q1 financial results, particularly the reduced net loss and increased revenue, alongside an extended cash runway into Q4 2026, indicate progress in managing its burn rate. More importantly, the positive interim Phase 3 data for Ovaprene and the imminent launch of Flora Sync LF5, marking the company's first direct product revenue, represent significant milestones in its transition to a revenue-generating entity. These developments, alongside the advancement of DARE-HPV with non-dilutive funding, suggest a diversified pipeline and multiple pathways to value, which could significantly de-risk the investment thesis.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DARE was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $1.27 to $9.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DARE - Latest Insights

DARE
Oct 06, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.844
Real-time Price: $0.6096 info
Change: -$0.2344 (-28%) info
Market Cap: $11.991M info
DARE
Oct 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8428
Real-time Price: $0.6096 info
Change: -$0.2332 (-28%) info
Market Cap: $11.991M info
DARE
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.8074
Real-time Price: $0.6096 info
Change: -$0.1978 (-24%) info
Market Cap: $11.991M info
DARE
Aug 26, 2026, 5:15 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.6096 info
Change: -$0.2004 (-25%) info
Market Cap: $11.991M info
DARE
Aug 17, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.900
Real-time Price: $0.6096 info
Change: -$0.2904 (-32%) info
Market Cap: $11.991M info